High‐intensity vs. sham inspiratory muscle training in patients with chronic heart failure: a prospective randomized trial. (August 2013)
- Record Type:
- Journal Article
- Title:
- High‐intensity vs. sham inspiratory muscle training in patients with chronic heart failure: a prospective randomized trial. (August 2013)
- Main Title:
- High‐intensity vs. sham inspiratory muscle training in patients with chronic heart failure: a prospective randomized trial
- Authors:
- Marco, Ester
Ramírez‐Sarmiento, Alba L.
Coloma, Ana
Sartor, Monique
Comin‐Colet, Josep
Vila, Joan
Enjuanes, Cristina
Bruguera, Jordi
Escalada, Ferran
Gea, Joaquim
Orozco‐Levi, Mauricio - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ejhfhft035-sec-0001" sec-type="section"> <title>Aims</title> <p>The purpose of this study was to evaluate the effectiveness, feasibility, and safety of a 4‐week high‐intensity inspiratory muscle training (hi‐IMT) in patients with chronic heart failure (CHF).</p> </sec> <sec id="ejhfhft035-sec-0002" sec-type="section"> <title>Methods and results</title> <p>A double‐blind randomized clinical trial was carried out in 22 patients with CHF. Participants were assigned to the hi‐IMT or sham‐IMT group. The trainer device was a prototype of the Orygen‐Dual Valve<sup>®</sup>. The training workloads were adjusted weekly at the inspiratory pressure which allowed the performance of 10 consecutive maximal repetitions (10RM). Main outcomes were strength and endurance of the respiratory muscles assessed by maximal respiratory pressures (PI<sub>max</sub> and PE<sub>max</sub>) and a 10RM manoeuvre, respectively. Twenty‐one patients presented impairment in respiratory muscle strength and endurance. Patients in the hi‐IMT group showed a significant improvement in both strength and endurance: inspiratory muscle strength in the intervention group increased 57.2% compared with 25.9% in the control group (<italic>P</italic> = 0.001). The percentage change in endurance was 72.7% for the hi‐IMT group compared with 18.2% in the sham‐IMT group (<italic>P</italic> &lt; 0.001). No adverse effects occurred<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ejhfhft035-sec-0001" sec-type="section"> <title>Aims</title> <p>The purpose of this study was to evaluate the effectiveness, feasibility, and safety of a 4‐week high‐intensity inspiratory muscle training (hi‐IMT) in patients with chronic heart failure (CHF).</p> </sec> <sec id="ejhfhft035-sec-0002" sec-type="section"> <title>Methods and results</title> <p>A double‐blind randomized clinical trial was carried out in 22 patients with CHF. Participants were assigned to the hi‐IMT or sham‐IMT group. The trainer device was a prototype of the Orygen‐Dual Valve<sup>®</sup>. The training workloads were adjusted weekly at the inspiratory pressure which allowed the performance of 10 consecutive maximal repetitions (10RM). Main outcomes were strength and endurance of the respiratory muscles assessed by maximal respiratory pressures (PI<sub>max</sub> and PE<sub>max</sub>) and a 10RM manoeuvre, respectively. Twenty‐one patients presented impairment in respiratory muscle strength and endurance. Patients in the hi‐IMT group showed a significant improvement in both strength and endurance: inspiratory muscle strength in the intervention group increased 57.2% compared with 25.9% in the control group (<italic>P</italic> = 0.001). The percentage change in endurance was 72.7% for the hi‐IMT group compared with 18.2% in the sham‐IMT group (<italic>P</italic> &lt; 0.001). No adverse effects occurred during the intervention.</p> </sec> <sec id="ejhfhft035-sec-0003" sec-type="section"> <title>Conclusion</title> <p>A 4‐week hi‐IMT with the use of the Orygen‐Dual Valve<sup>®</sup> is shown to be an effective, feasible, and safe tool to improve weakness and fatigue of the inspiratory muscles. The key point of this study is to discuss immediate practical implications in terms of respiratory muscle dysfunction postulated as a potential prognostic factor and as an additional therapeutic target.</p> </sec> <sec id="ejhfhft035-sec-0004" sec-type="section"> <title>Trials registration</title> <p>NCT01606553.</p> </sec> </abstract> … (more)
- Is Part Of:
- European journal of heart failure. Volume 15:Number 8(2013)
- Journal:
- European journal of heart failure
- Issue:
- Volume 15:Number 8(2013)
- Issue Display:
- Volume 15, Issue 8 (2013)
- Year:
- 2013
- Volume:
- 15
- Issue:
- 8
- Issue Sort Value:
- 2013-0015-0008-0000
- Page Start:
- 892
- Page End:
- 901
- Publication Date:
- 2013-08
- Subjects:
- Heart failure -- Periodicals
Heart Failure -- Periodicals
Insuffisance cardiaque -- Périodiques
Heart failure
Periodicals
616.129005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1879-0844 ↗
http://rave.ohiolink.edu/ejournals/issn/13889842/ ↗
http://www.sciencedirect.com/science/journal/13889842 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1093/eurjhf/hft035 ↗
- Languages:
- English
- ISSNs:
- 1388-9842
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.729860
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3514.xml